Cambridge Investment Research Advisors
EPZM

Cambridge Investment Research Advisors’s Epizyme, Inc EPZM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,500
Closed -$64K – 3310
2021
Q3 		$64K Hold
12,500
– – ﹤0.01% 3008
2021
Q2 		$104K Hold
12,500
– – ﹤0.01% 2967
2021
Q1 		$109K Buy
+12,500
New +$129K ﹤0.01% 2746

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Cambridge Investment Research Advisors's EPZM Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 12,500 shares — an estimated $64K sold.

Cambridge Investment Research Advisors first reported a position in EPZM in Q1 2021 and held it in 3 quarters. The position peaked at $109K in Q1 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 12,500 Epizyme, Inc shares in Q4 2021, an estimated $64K.
  • Cambridge Investment Research Advisors first reported a position in Epizyme, Inc in Q1 2021 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Epizyme, Inc position peaked at $109K in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.